Targeted drugs such as tumor necrosis factor alpha antagonists (TNF-alpha) (e.g., infliximab) and interleukin-6 receptor (IL-6R) antagonist (e.g., tocilizumab), as well as inhibitors of janus kinases (JAKs) (e.g., tofacitinib), have markedly advanced the treatment of RA [3,4,5]. The gene discussed is IL6R; the disease is rheumatoid arthritis.